Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.99
ISIS's Cash to Debt is ranked higher than
68% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ISIS: 7.99 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.34   Max: 7.99
Current: 7.99

0.34
7.99
Equity to Asset 0.45
ISIS's Equity to Asset is ranked higher than
58% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ISIS: 0.45 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.76
Current: 0.45

-0.35
0.76
F-Score: 6
Z-Score: 4.25
M-Score: 9.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -35.08
ISIS's Operating margin (%) is ranked higher than
73% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ISIS: -35.08 )
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91   Max: -12.18
Current: -35.08

-438.91
-12.18
Net-margin (%) -41.17
ISIS's Net-margin (%) is ranked higher than
72% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ISIS: -41.17 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33   Max: 127.52
Current: -41.17

-334.33
127.52
ROE (%) -16.03
ISIS's ROE (%) is ranked higher than
73% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ISIS: -16.03 )
ISIS' s 10-Year ROE (%) Range
Min: -7400   Max: 53.16
Current: -16.03

-7400
53.16
ROA (%) -7.16
ISIS's ROA (%) is ranked higher than
77% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ISIS: -7.16 )
ISIS' s 10-Year ROA (%) Range
Min: -68.37   Max: 23.6
Current: -7.16

-68.37
23.6
ROC (Joel Greenblatt) (%) -59.94
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ISIS: -59.94 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -911.25   Max: -57.54
Current: -59.94

-911.25
-57.54
Revenue Growth (%) 6.90
ISIS's Revenue Growth (%) is ranked higher than
80% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ISIS: 6.90 )
ISIS' s 10-Year Revenue Growth (%) Range
Min: -39.4   Max: 83.7
Current: 6.9

-39.4
83.7
EBITDA Growth (%) -4.50
ISIS's EBITDA Growth (%) is ranked higher than
79% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ISIS: -4.50 )
ISIS' s 10-Year EBITDA Growth (%) Range
Min: -49.6   Max: 61.3
Current: -4.5

-49.6
61.3
EPS Growth (%) -3.90
ISIS's EPS Growth (%) is ranked higher than
80% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ISIS: -3.90 )
ISIS' s 10-Year EPS Growth (%) Range
Min: -71.2   Max: 117.8
Current: -3.9

-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ISIS Guru Trades in Q1 2013

Steven Cohen 19,433 sh (New)
Louis Moore Bacon 125,000 sh (New)
Murray Stahl 17,000 sh (-41.38%)
» More
Q2 2013

ISIS Guru Trades in Q2 2013

Jim Simons 27,914 sh (New)
Steven Cohen 27,107 sh (+39.49%)
Murray Stahl 17,000 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q3 2013

ISIS Guru Trades in Q3 2013

Jim Simons 328,914 sh (+1078.31%)
Steven Cohen 67,399 sh (+148.64%)
Murray Stahl 17,000 sh (unchged)
» More
Q4 2013

ISIS Guru Trades in Q4 2013

Murray Stahl 17,000 sh (unchged)
Jim Simons 326,114 sh (-0.85%)
Steven Cohen 8,531 sh (-87.34%)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-06-30 Sold Out $8.54 - $9.38 $ 34.01281%0
George Soros 2011-03-31 New Buy$8.57 - $10.35 $ 34.01269%22300
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.40
ISIS's P/B is ranked lower than
61% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ISIS: 10.40 )
ISIS' s 10-Year P/B Range
Min: 2.79   Max: 1710
Current: 10.4

2.79
1710
P/S 25.50
ISIS's P/S is ranked lower than
67% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ISIS: 25.50 )
ISIS' s 10-Year P/S Range
Min: 3.85   Max: 84.47
Current: 25.5

3.85
84.47
PFCF 68.00
ISIS's PFCF is ranked lower than
64% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ISIS: 68.00 )
ISIS' s 10-Year PFCF Range
Min: 3.7   Max: 198.35
Current: 68

3.7
198.35
EV-to-EBIT 100.00
ISIS's EV-to-EBIT is ranked lower than
78% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ISIS: 100.00 )
ISIS' s 10-Year EV-to-EBIT Range
Min: 379   Max: 580.4
Current: 100

379
580.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.10
ISIS's Price/Net Cash is ranked lower than
69% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ISIS: 21.10 )
ISIS' s 10-Year Price/Net Cash Range
Min: 5.27   Max: 139
Current: 21.1

5.27
139
Price/Net Current Asset Value 19.80
ISIS's Price/Net Current Asset Value is ranked lower than
67% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ISIS: 19.80 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 5.03   Max: 101.09
Current: 19.8

5.03
101.09
Price/Tangible Book 10.90
ISIS's Price/Tangible Book is ranked lower than
65% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ISIS: 10.90 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 1.87   Max: 216.67
Current: 10.9

1.87
216.67
Price/DCF (Projected) 22.80
ISIS's Price/DCF (Projected) is ranked lower than
76% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ISIS: 22.80 )
ISIS' s 10-Year Price/DCF (Projected) Range
Min: 26.74   Max: 26.74
Current: 22.8

Price/Median PS Value 2.60
ISIS's Price/Median PS Value is ranked lower than
67% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ISIS: 2.60 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 5.64
Current: 2.6

0.46
5.64
Forward Rate of Return (Yacktman) -0.63
ISIS's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ISIS: -0.63 )
ISIS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.8   Max: -6.4
Current: -0.63

-8.8
-6.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISI.Germany
Isis Pharmaceuticals was incorporated in California on January 10, 1989, and reorganized as a Delaware corporation in April 1991. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 28 drugs in development that represents the potential for significant commercial opportunities in many therapeutic areas. It was successful in bringing KYNAMRO to the market for patients with HoFH. These patients are at high cardiovascular risk and may not be able to reduce their LDL-C sufficiently with currently available lipid-lowering therapies. In addition to KYNAMRO, many of the other drugs in its pipeline are demonstrating encouraging clinical activity in a variety of diseases. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide